mercoledì, 19 giugno 2024
15 Novembre 2016

FDA Grants Brentuximab Vedotin Breakthrough Designation in CTCL

Brentuximab vedotin has received an FDA breakthrough therapy designation for the treatment of patients with CD30-positive mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) following at least 1 prior systemic therapy, according to Seattle Genetics, the manufacturer of the anti-CD30 antibody-drug conjugate.The designation, which will expedite the development and review of brentuximab vedotin for use in these 2 most common subtypes … (leggi tutto)